Business Description
Dermapharm Holding SE
ISIN : DE000A2GS5D8
Share Class Description:
WBO:DMP: Bearer SharesCompare
Compare
Traded in other countries / regions
DMP.Germany0A5J.UKDMP.AustriaDMPHF.USA IPO Date
2024-09-26Description
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals and other healthcare products which drive key revenue, Herbal extracts, and Parallel import business. Branded pharmaceuticals and other healthcare products focus on the development, manufacturing, and marketing of branded pharmaceuticals and other healthcare products. Herbal extracts include the manufacturing of phytopharmaceuticals, nutraceuticals, and cosmetics products. Parallel import brands business operates under the AxiCorp brand.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.16 | |||||
| Equity-to-Asset | 0.25 | |||||
| Debt-to-Equity | 1.96 | |||||
| Debt-to-EBITDA | 3.73 | |||||
| Interest Coverage | 3.08 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 1.79 | |||||
| Beneish M-Score | -2.86 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.7 | |||||
| 3-Year EBITDA Growth Rate | 13 | |||||
| 3-Year EPS without NRI Growth Rate | -13.5 | |||||
| 3-Year FCF Growth Rate | 25.4 | |||||
| 3-Year Book Growth Rate | 18.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 31.19 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 4.37 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 28.72 | |||||
| 9-Day RSI | 22.96 | |||||
| 14-Day RSI | 21.19 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.58 | |||||
| Quick Ratio | 0.78 | |||||
| Cash Ratio | 0.39 | |||||
| Days Inventory | 301.15 | |||||
| Days Sales Outstanding | 36.18 | |||||
| Days Payable | 81.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Dividend Growth Rate | 9.5 | |||||
| Shareholder Yield % | -13.5 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 64.32 | |||||
| Operating Margin % | 16.64 | |||||
| Net Margin % | 7.34 | |||||
| FCF Margin % | 12.86 | |||||
| ROE % | 15.15 | |||||
| ROA % | 3.84 | |||||
| ROIC % | 6.42 | |||||
| 3-Year ROIIC % | 0.42 | |||||
| ROC (Joel Greenblatt) % | 40.54 | |||||
| ROCE % | 10.69 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 20.13 | |||||
| Forward PE Ratio | 13.31 | |||||
| PE Ratio without NRI | 20.13 | |||||
| Shiller PE Ratio | 17.98 | |||||
| Price-to-Owner-Earnings | 12.45 | |||||
| PEG Ratio | 1.12 | |||||
| PS Ratio | 1.48 | |||||
| PB Ratio | 3.03 | |||||
| Price-to-Free-Cash-Flow | 11.5 | |||||
| Price-to-Operating-Cash-Flow | 8.94 | |||||
| EV-to-EBIT | 13.57 | |||||
| EV-to-EBITDA | 8.94 | |||||
| EV-to-Revenue | 2.29 | |||||
| EV-to-FCF | 17.79 | |||||
| Price-to-Projected-FCF | 0.66 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.17 | |||||
| Earnings Yield (Greenblatt) % | 7.37 | |||||
| FCF Yield % | 8.72 | |||||
| Forward Rate of Return (Yacktman) % | 26.22 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Dermapharm Holding SE Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1,131.757 | ||
| EPS (TTM) (€) | 1.54 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 21.19 | ||
| 14-Day ATR (€) | 0.520356 | ||
| 20-Day SMA (€) | 0 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 31.1 - 35.6 | ||
| Shares Outstanding (Mil) | 53.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Dermapharm Holding SE Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Dermapharm Holding SE Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Dermapharm Holding SE Frequently Asked Questions
What is Dermapharm Holding SE(WBO:DMP)'s stock price today?
The current price of WBO:DMP is €31.50. The 52 week high of WBO:DMP is €35.60 and 52 week low is €31.10.
When is next earnings date of Dermapharm Holding SE(WBO:DMP)?
The next earnings date of Dermapharm Holding SE(WBO:DMP) is .
Does Dermapharm Holding SE(WBO:DMP) pay dividends? If so, how much?
Dermapharm Holding SE(WBO:DMP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers